This article is more than 5 years old. Information may no longer be current.
Patients with psoriasis treated with Humira had correlation between adipokines, disease severity
Among patients with moderate-to-severe psoriasis treated with Humira, correlations were found between leptin and metabolic syndrome and inflammation, and between resistin and inflammation and disease severity, according to study results.
Researchers in Spain evaluated whether leptin and resistin, two adipokines, correlated with metabolic syndrome and disease severity in patients with psoriasis. They conducted a prospective study of 29 non-diabetic patients with moderate-to-severe psoriasis who completed therapy with Humira (adalimumab, AbbVie) for 6 months. Exclusion criteria included kidney disease, hypertension or BMI of at least 35 kg/m2. At treatment onset and month 6, a metabolic and clinical evaluation was conducted.
At 6 months, there was a correlation between adiposity and leptin (P = .03). Blood pressure prior to therapy also correlated with leptin (systolic, P = .013; diastolic, P = .01). Insulin sensitivity and leptin levels had a “marginally significant negative correlation,” the researchers wrote.
There was a correlation between C-reactive protein (CRP) levels and leptin before treatment (P = .02), and between CRP and resistin before therapy (P = .02) and after 6 months of therapy (P = .004).
Prior to starting adalimumab therapy, there was a positive association between resistin and body surface area and resistin and Psoriasis Area and Severity Index (P = .001, both).
“No significant changes in leptin and resistin concentrations before and after 6 month adalimumab treatment were seen,” the researchers wrote. – By Bruce Thiel
Reference:
Murcia CP, et al. Paper #AB0077. Presented at: European League Against Rheumatism Annual European Congress of Rheumatology; June 10-13, 2015; Rome.
Disclosures: AbbVie funded the study. The researchers report no relevant financial disclosures.